Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference:
2021 Cantor Virtual Global Healthcare Conference; Wednesday, September 29th, at 8:40 a.m. Pacific Time
The investor conference presentation will be webcast live and may be accessed through a link on the investors section of Inhibrx’s website at
About Inhibrx, Inc.
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.
Investor and Media Contact:
SOURCE Inhibrx, Inc.